CRL
Charles River Laboratories International, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Charles River Laboratories International, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Last report3 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
No other changes.
No other changes.
No thesis.
Annual filing, covered
10-K parsed · Feb 18 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 18 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
+11.36%
vs ±14.0% implied · ×0.81
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
shaded = implied · ▲▼ = realized
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $961.5M | 7.47% | +22.67% |
| BlackRockindex-like | $861.5M | 6.69% | −1.57% |
| Vanguardindex-like | $714.2M | 5.55% | −1.65% |
| Invesco | $676.9M | 5.26% | new |
| Harris Associates L P | $508.3M | 3.95% | +4.08% |
| Manager | Value | % base | |
|---|---|---|---|
| FMR | $961.5M | 7.47% | +22.67% |
| BlackRockindex-like | $861.5M | 6.69% | −1.57% |
| Vanguardindex-like | $714.2M | 5.55% | −1.65% |
| Invesco | $676.9M | 5.26% | new |
| Harris Associates L P | $508.3M | 3.95% | +4.08% |
Charles River Laboratories International, Inc.
351.73
+13.19 · +3.89%
post 351.87 +0.04%
Bull2
Bear2
Same SIC code · 6
Same SEC industry code: Iqvia Holdings Inc., Incyte Corp, Medpace Holdings, Inc. and 3 more; of Charles River Laboratories International, Inc.'s 6 closest co-movers, 1 shares that code.
Same SIC code · 6
Same SEC industry code: Iqvia Holdings Inc., Incyte Corp, Medpace Holdings, Inc. and 3 more; of Charles River Laboratories International, Inc.'s 6 closest co-movers, 1 shares that code.
Linked news
Tall tick = annual report · Source: EDGAR
—
Expected move
Inputs8Q avg ±6.7%·×1.19·rich
straddle ±10.4%
spot 351.87exp Nov 20ATM strike 350ATM straddle 42.90IV 71%